Neuland Laboratories Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹25.6K Cr

Neuland expects strong growth in sales/revenue for FY26, building on the FY24 base. Management expects strong revenue growth in FY26 and beyond, driven by commercial CMS projects, new molecule commercializations, and peptide segment expansion.

From Neuland Laboratories Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹23,301

Market Cap

₹25.6K Cr

P/E Ratio

51.4

How does Neuland Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Neuland Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Neuland Laboratories Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹776 Cr, net profit ₹213 Cr.

Full financials →

📊 Revenue & Sales Performance

→Neuland expects strong growth in sales/revenue for FY26, building on the FY24 base.
→Management calls for a "healthy" to "strong" growth but refrains from specific numerical guidance.
→The company anticipates a 20% CAGR over a 3-5 year horizon as a reasonable benchmark.
→Growth drivers include commercial molecules scaling up, new business from existing and new customers, and commercialization of additional CMS molecules.
→Expansion in peptide and specialty APIs is also expected to contribute significantly.
→Capacity expansions (such as Unit 3 production block) are expected to support growth in the latter half of FY26.
→Lumpiness in revenues is expected to reduce as portfolios mature and capacity constraints ease.
→Overall, management is optimistic about long-term opportunities and increased CMS contribution to revenues.

📈 Profitability & Margins

→Management expects strong revenue growth in FY26 and beyond, driven by commercial CMS projects, new molecule commercializations, and peptide segment expansion.
→Over a 3-5 year horizon, a 20% CAGR in revenues is considered reasonable, though no precise guidance for FY26 is provided.
→Margins in FY26 are expected to recover from recent suppression caused by low sales and de-leverage, aiming to return to strong EBITDA margins comparable to FY24.
→EBITDA margin in FY24 was exceptional (~30%+), but future margins depend on sales scale-up and commercial dynamics; no specific margin guidance given for upcoming years.
→EPS and profits are expected to improve aligned with revenue and margin recovery, with company focusing on cost optimization for long-term sustainability.
→Management remains cautious, providing qualitative "strong growth" outlook without specific numeric targets for profits or EPS in the near term.

See what Neuland Laboratories Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→CAPEX for FY26 is around Rs. 250 crores.
→Approximately 60% of this CAPEX is for growth, 40% for maintenance.
→Investments are being made in expanding capacity, including a new production block in Unit 3 (expected to be operational by August/September).
→Expansion of Unit 1 is underway, involving acquisition of additional land to enable faster capacity addition compared to Greenfield projects.
→Peptide facility being built on acquired land next to Unit 1, expected to be completed in the next financial year.
→Capacity for CMS molecules is mostly aligned for the next 2-3 years, though monitoring and tweaks continue.
→Neuland is investing in capabilities for peptides, deuterated molecules, and other specialized projects to differentiate itself and build long-term growth.

💰 Fundraising & Capital Structure

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company reported a net debt position of negative Rs. 165 crores, indicating a net cash position.
→CAPEX spending is ongoing (around Rs. 250 crores for FY26), funded through existing resources.
→Management discussed focusing on balancing growth and profitability while optimizing costs, with no indication of raising new capital.
→They continue to evaluate opportunities for long-term growth but have not indicated any financing plans via new debt or equity issuance.

See what Neuland Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The management did not specify exact numbers for the current or expected orderbook during the call.
→Saharsh Davuluri acknowledged the importance of attending to the orderbook but did not provide detailed figures.
→There is mention of a healthy customer pipeline providing good visibility for future revenue.
→Growth is expected to pick up in the latter half of FY26 with the commercialization of the Unit 3 production block.
→New business from both existing and new customers is showing significant momentum, expected to realize over FY26 and FY27.
→The company continues to see increased interest and first-time orders from customers, indicating a robust order pipeline.
→Lumpiness in order flow is recognized as a business characteristic, expected to reduce as the company scales and commercializes more molecules.

Key Metrics

What Neuland Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Sigachi Industries Ltd (Q1 FY26)
INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia). Key concall takeaways from Sigachi Industries Ltd's…
Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Neuland Laboratories Ltd Q1 FY26 results?

What is Neuland Laboratories Ltd share price analysis?

Neuland Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 51.4 with a market cap of ₹25,603 Cr. Investors should review the full earnings analysis for detailed insights.

Is Neuland Laboratories Ltd planning capital expenditure?

CAPEX for FY26 is around Rs.

Keep Neuland Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.